INI-822 (A)

Phase 1Small molecule

IInipharm Australia Pty Ltd

INI-822 (A) is one of 50 small molecule programs targeting Non-Alcoholic Steatohepatitis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Alcoholic SteatohepatitisActive, not recruiting

Non-Alcoholic SteatohepatitisPhase 1

Active, not recruiting

Competition

Competitive Landscape

96 competitors in Non-Alcoholic Steatohepatitis

#DrugCompanyPhaseTrials

Ozempic

Novo Nordisk

Phase 3

4 2

Victoza

Novo Nordisk

Phase 3

2 3

Uloric

Takeda

Phase 2

1 4

Farxiga

AstraZeneca

Phase 2

1 5

Diosmin

TTanta University

Phase 3

1 6

Metadoxine

AAlcobra Ltd.

Phase 3

1 7

Efruxifermin

Akero Therapeutics

Phase 3

1 8

Dipeptidyl Peptidase 4 Inhibitor

Boehringer Ingelheim

Phase 3

1 9

Zetia

OOrganon and Co

Phase 2

2 10

Legalon

BBukwang Pharmaceutical

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Non-Alcoholic Steatohepatitis1 trial

A Study of INI-822 in Healthy Volunteers and Participants with Non-alcoholic Steatohepatitis (NASH) or Presumed NASH

Recruiting·IInipharm Australia Pty Ltd·Phase 1·NCT05945537·104 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for INI-822 (A). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — INI-822 (A) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for INI-822 (A). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Inipharm Australia Pty Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: IInipharm Australia Pty Ltd

INI-822 (A)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Non-Alcoholic Steatohepatitis1 trial

References

Drug Info

Quick Facts

Related News